세계의 줄기세포 치료제 위탁생산 시장(2023-2033년)

Stem Cell Therapy Contract Manufacturing Market Report 2023-2033

￡ 3,950 ￦ 7,416,000

Unprintable PDF (Single User) - 1 Year License

보고서 PDF를 1명만 이용할 수 있는 라이선스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF(이용기간은 구매일로부터 1년)로 제공되며, 인증된 PC 1대에서만 열람 가능합니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

￡ 4,500 ￦ 8,449,000

PDF (Team License - Up to 6 Users) - 1 Year License

보고서 PDF를 동일 사업장(소재지) 내의 6명까지 이용할 수 있는 라이선스입니다. PDF 내 텍스트 등의 Copy&Paste는 불가능합니다. DRM(디지털 저작권 관리 시스템) 장착 PDF(이용기간은 구매일로부터 1년)이며, 인증된 PC상에서 열람 가능합니다. 인쇄는 1명당 1회만 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 5,500 ￦ 10,326,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 1명당 1회만 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 6,950 ￦ 13,049,000

PDF (Enterprise License - Includes Free Datasets)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 줄기세포 치료제 위탁생산 시장 규모는 2033년까지 12.4%의 CAGR을 나타낼 것으로 예상됩니다.

세포생물학 및 재생의료 분야의 발전은 심혈관, 종양, 대사 및 근골격계 질환을 치료하기 위한 줄기세포 중심 치료법의 출현을 위한 탄탄한 토대를 마련했습니다. 이러한 혁신적인 치료법은 세계 환자들에게 밝은 전망을 제시하며, 복잡한 의학적 문제를 해결하기 위한 전략과 전술을 변화시킬 수 있는 전망을 제시하고 있습니다. 이 분야에 대한 지속적인 탐구와 노력으로 질병을 효과적으로 관리하고 근절하기 위한 진전을 이룰 수 있을 것으로 기대됩니다.

세계 줄기세포 치료제 위탁생산 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter의 Five Forces 분석
• PEST 분석

제4장 줄기세포 치료제 수탁 제조 시장 분석 : 사업 스케일별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 상업
• 임상
• 전임상

제5장 줄기세포 치료제 수탁 제조 시장 분석 : 수탁 제조업체 규모별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 대규모/초대형 규모
• 중규모
• 소규모

제6장 줄기세포 치료제 수탁 제조 시장 분석 : 줄기세포 공급원별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 동종 줄기세포
• 자가 줄기세포

제7장 줄기세포 치료제 수탁 제조 시장 분석 : 줄기세포 유형별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 성인 줄기세포
• 인간 배성간세포(HESC)
• 유도만능 줄기세포(iPSC)

제8장 줄기세포 치료제 수탁 제조 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산 및 예측
• 바이오의약품 기업
• 연구기관
• 기타

제9장 줄기세포 치료제 수탁 제조 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제10장 북미의 줄기세포 치료제 수탁 제조 시장 분석

제11장 유럽의 줄기세포 치료제 수탁 제조 시장 분석

제12장 아시아태평양의 줄기세포 치료제 수탁 제조 시장 분석

제13장 라틴아메리카의 줄기세포 치료제 수탁 제조 시장 분석

제14장 중동 및 아프리카의 줄기세포 치료제 수탁 제조 시장 분석

제15장 기업 개요

• 기업 점유율 분석
• 전략적 전망
• AbbVie Inc.
• AGC Biologics
• Boehringer Ingelheim GmbH
• Catalent Inc.
• FUJIFILM Diosynth Biotechnologies
• Lonza
• Pfizer Inc.
• Samsung Biologics
• WuXi AppTec
• Thermo Fisher Scientific Inc.
• Cytiva

제16장 결론 및 제안

LSH

영문 목차

영문목차

The global Stem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033.

“The Stem Cell Therapy Contract Manufacturing Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Advances in Cell Biology and Regenerative Medicine Propels Stem Cell Therapy Market Consequently boosting the Contract Manufacturing market

The progress in the realm of cell biology and regenerative medicine has laid a solid foundation for the emergence of therapies centered on stem cells, aimed at addressing an array of cardiovascular, oncological, metabolic, and musculoskeletal disorders. These innovative treatments hold promise for patients across the globe, presenting the prospect of transforming our strategies and tactics for handling these intricate medical challenges. Sustained exploration and inventive endeavours within this domain will undeniably lead to additional milestones, propelling us towards a tomorrow in which incapacitating illnesses can be managed with effectiveness, and in some cases, even eradicated. For instance, Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics are using CRISPR-Cas9 gene editing technology for potential gene therapies and regenerative medicine applications, aiming to correct genetic disorders at the molecular level. Also, Vericel's MACI (Matrix-Induced Autologous Chondrocyte Implantation) is an FDA-approved product that uses a patient's own cells to repair cartilage defects in the knee.

Challenges Posed by Immunogenicity and Potential for Rejection in Stem Cell Therapy is Restraining the Market Growth

Immunogenicity-related issues encountered during clinical trials can result in trial delays, the need for further research, and adjustments to therapy design. These setbacks have the potential to extend the development timeline and elevate costs, possibly deterring investments and impeding market expansion. Should stem cell therapies be prone to immune rejection, their sustained effectiveness and durability might be compromised. This has the potential to erode patient trust in the therapy and curtail the market demand for treatments lacking enduring advantages. The challenges posed by immunogenicity and the prospect of rejection in stem cell therapy can significantly influence market growth. Immunogenicity pertains to the capacity of stem cell therapies to trigger immune reactions within recipients. These responses may lead to the rejection of transplanted cells, curbing therapy efficacy and raising safety concerns. Patients experiencing rejection may not attain the intended therapeutic outcomes, resulting in less-than-optimal treatment results.

What Questions Should You Ask before Buying a Market Research Report?

• How is the stem cell therapy contract manufacturing market evolving?
• What is driving and restraining the stem cell therapy contract manufacturing market?
• How will each stem cell therapy contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each stem cell therapy contract manufacturing submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading stem cell therapy contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the stem cell therapy contract manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of stem cell therapy contract manufacturing projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the stem cell therapy contract manufacturing market?
• Where is the stem cell therapy contract manufacturing market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the stem cell therapy contract manufacturing market today, and over the next 10 years:

• Our 310-page report provides 111 tables and 185 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Stem Cell Therapy Contract Manufacturing Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Scale of Operation Outlook

• Commercial
• Clinical
• Preclinical

Size of Contract Manufacturer

• Large/Very Large
• Mid-sized
• Small-sized

Source of Stem Cells

• Allogenic
• Autologous

Type of Stem Cells

• Adult Stem Cells (ASCs)
• Human Embryonic Stem Cells (HESCs)
• Induced Pluripotent Stem Cells (iPSCs)

End-user

• Biopharmaceutical companies
• Research Institutes
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Stem Cell Therapy Contract Manufacturing Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

Overall world revenue for Stem Cell Therapy Contract Manufacturing Market, 2023 to 2033 in terms of value the market will surpass US$2,752.1 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Stem Cell Therapy Contract Manufacturing Market, 2023 to 2033 report help you?

In summary, our 310-page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Stem Cell Therapy Contract Manufacturing Market, 2023 to 2033 Market, with forecasts for scale of operation, size of contract manufacturer, source of stem cells, type of stem cells, and end-user, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 18 key national markets - See forecasts for the Stem Cell Therapy Contract Manufacturing Market, 2023 to 2033 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Stem Cell Therapy Contract Manufacturing Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Stem Cell Therapy Contract Manufacturing Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Stem Cell Therapy Contract Manufacturing Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Reports
• 1.10 About

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Increasing Product Development of Stem Cell Therapy Driving the Demand for Contract Manufacturing Solutions
    • 3.2.1.2 Growing Venture Capital Investments in Stem Cell Based Therapies
    • 3.2.1.3 Supportive Regulations Pertinent to the Development of Stem Cell Therapy Contract Manufacturing
    • 3.2.1.4 Rising Prevalence of Chronic Diseases
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Complex Manufacturing Process
    • 3.2.2.2 Challenges Posed by Immunogenicity and the Potential for Rejection in Stem Cell Therapy
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Strong Product Pipeline
    • 3.2.3.2 Advancements in Stem Cell Therapy Manufacturing Process
    • 3.2.3.3 Advances in Cell Biology and Regenerative Medicine
    • 3.2.3.4 Collaboration and M&A Driving the Market Growth
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis

4 Stem Cell Therapy Contract Manufacturing Market Analysis by Scale of Operation

• 4.1 Key Findings
• 4.2 Scale of Operation Segment: Market Attractiveness Index
• 4.3 Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 4.4 Commercial
  • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Clinical
  • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)
• 4.6 Pre-clinical
  • 4.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.6.2 Market Share by Region, 2023 & 2033 (%)

5 Stem Cell Therapy Contract Manufacturing Market Analysis by Size of Contract Manufacturer

• 5.1 Key Findings
• 5.2 Size of Contract Manufacturer Segment: Market Attractiveness Index
• 5.3 Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Size of Contract Manufacturer
• 5.4 Large/Very Large Contract Manufacturers
  • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Mid-Sized Contract Manufacturers
  • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Small-sized Contract Manufacturers
  • 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Stem Cell Therapy Contract Manufacturing Market Analysis by Source of Stem Cells

• 6.1 Key Findings
• 6.2 Source of Stem Cells Segment: Market Attractiveness Index
• 6.3 Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Source of Stem Cells
• 6.4 Allogenic Stem Cells
  • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 Autologous Stem Cells
  • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)

7 Stem Cell Therapy Contract Manufacturing Market Analysis by Type of Stem Cells

• 7.1 Key Findings
• 7.2 Type of Stem Cells Segment: Market Attractiveness Index
• 7.3 Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Type of Stem Cells
• 7.4 Adult Stem Cells
  • 7.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 7.4.2 Market Share by Region, 2023 & 2033 (%)
• 7.5 Human Embryonic Stem Cells (HESCs)
  • 7.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 7.5.2 Market Share by Region, 2023 & 2033 (%)
• 7.6 Induced Pluripotent Stem Cells (iPSCs)
  • 7.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 7.6.2 Market Share by Region, 2023 & 2033 (%)

8 Stem Cell Therapy Contract Manufacturing Market Analysis by End-User

• 8.1 Key Findings
• 8.2 End-User Segment: Market Attractiveness Index
• 8.3 Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by End-User
• 8.4 Biopharmaceutical Companies
  • 8.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.4.2 Market Share by Region, 2023 & 2033 (%)
• 8.5 Research Institutes
  • 8.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.5.2 Market Share by Region, 2023 & 2033 (%)
• 8.6 Others
  • 8.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 8.6.2 Market Share by Region, 2023 & 2033 (%)

9 Stem Cell Therapy Contract Manufacturing Market Analysis by Region

• 9.1 Key Findings
• 9.2 Regional Market Size Estimation and Forecast

10 North America Stem Cell Therapy Contract Manufacturing Market Analysis

• 10.1 Key Findings
• 10.2 North America Stem Cell Therapy Contract Manufacturing Market Attractiveness Index
• 10.3 North America Stem Cell Therapy Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 10.4 North America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Country
• 10.5 North America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 10.6 North America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Size of Contract Manufacturer
• 10.7 North America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Source of Stem Cells
• 10.8 North America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Type of Stem Cells
• 10.9 North America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by End-user
• 10.10 U.S. Stem Cell Therapy Contract Manufacturing Market Analysis
• 10.11 Canada Stem Cell Therapy Contract Manufacturing Market Analysis

11 Europe Stem Cell Therapy Contract Manufacturing Market Analysis

• 11.1 Key Findings
• 11.2 Europe Stem Cell Therapy Contract Manufacturing Market Attractiveness Index
• 11.3 Europe Stem Cell Therapy Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 11.4 Europe Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Country
• 11.5 Europe Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 11.6 Europe Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Size of Contract Manufacturer
• 11.7 Europe Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Source of Stem Cells
• 11.8 Europe Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Type of Stem Cells
• 11.9 Europe Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by End-user
• 11.10 Germany Stem Cell Therapy Contract Manufacturing Market Analysis
• 11.11 UK Stem Cell Therapy Contract Manufacturing Market Analysis
• 11.12 France Stem Cell Therapy Contract Manufacturing Market Analysis
• 11.13 Italy Stem Cell Therapy Contract Manufacturing Market Analysis
• 11.14 Spain Stem Cell Therapy Contract Manufacturing Market Analysis
• 11.15 Russia Stem Cell Therapy Contract Manufacturing Market Analysis
• 11.16 Rest of Europe Stem Cell Therapy Contract Manufacturing Market Analysis

12 Asia Stem Cell Therapy Contract Manufacturing Market Analysis

• 12.1 Key Findings
• 12.2 Asia Stem Cell Therapy Contract Manufacturing Market Attractiveness Index
• 12.3 Asia Stem Cell Therapy Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 12.4 Asia Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Country
• 12.5 Asia Pacific Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 12.6 Asia Pacific Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Size of Contract Manufacturer
• 12.7 Asia Pacific Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Source of Stem Cells
• 12.8 Asia Pacific Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Type of Stem Cells
• 12.9 Asia Pacific Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by End-user
• 12.10 Japan Stem Cell Therapy Contract Manufacturing Market Analysis
• 12.11 China Stem Cell Therapy Contract Manufacturing Market Analysis
• 12.12 India Stem Cell Therapy Contract Manufacturing Market Analysis
• 12.13 Australia Stem Cell Therapy Contract Manufacturing Market Analysis
• 12.14 South Korea Stem Cell Therapy Contract Manufacturing Market Analysis
• 12.15 Rest of Asia Stem Cell Therapy Contract Manufacturing Market Analysis

13 Latin America Stem Cell Therapy Contract Manufacturing Market Analysis

• 13.1 Key Findings
• 13.2 Latin America Stem Cell Therapy Contract Manufacturing Market Attractiveness Index
• 13.3 Latin America Stem Cell Therapy Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 13.4 Latin America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Country
• 13.5 Latin America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 13.6 Latin America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Size of Contract Manufacturer
• 13.7 Latin America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Source of Stem Cells
• 13.8 Latin America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Type of Stem Cells
• 13.9 Latin America Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by End-user
• 13.10 Brazil Stem Cell Therapy Contract Manufacturing Market Analysis
• 13.11 Mexico Stem Cell Therapy Contract Manufacturing Market Analysis
• 13.12 Argentina Stem Cell Therapy Contract Manufacturing Market Analysis
• 13.13 Rest of Latin America Stem Cell Therapy Contract Manufacturing Market Analysis

14 MEA Stem Cell Therapy Contract Manufacturing Market Analysis

• 14.1 Key Findings
• 14.2 MEA Stem Cell Therapy Contract Manufacturing Market Attractiveness Index
• 14.3 MEA Stem Cell Therapy Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
• 14.4 MEA Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Country
• 14.5 MEA Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 14.6 MEA Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Size of Contract Manufacturer
• 14.7 MEA Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Source of Stem Cells
• 14.8 MEA Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by Type of Stem Cells
• 14.9 MEA Stem Cell Therapy Contract Manufacturing Market Size Estimation and Forecast by End-user
• 14.10 GCC Stem Cell Therapy Contract Manufacturing Market Analysis
• 14.11 South Africa Stem Cell Therapy Contract Manufacturing Market Analysis
• 14.12 Rest of MEA Stem Cell Therapy Contract Manufacturing Market Analysis

15 Company Profiles

• 15.1 Company Share Analysis, 2022
• 15.2 Strategic Outlook
• 15.3 AbbVie Inc.
  • 15.3.1 Company Snapshot
  • 15.3.2 Company Overview
  • 15.3.3 Financial Analysis
    • 15.3.3.1 Net Revenue, 2017-2022
    • 15.3.3.2 R&D, 2017-2022
    • 15.3.3.3 Regional Market Shares, 2022
  • 15.3.4 Service Benchmarking
  • 15.3.5 Strategic Outlook
• 15.4 AGC Biologics
  • 15.4.1 Company Snapshot
  • 15.4.2 Company Overview
  • 15.4.3 Financial Analysis
  • 15.4.4 Service Benchmarking
  • 15.4.5 Strategic Outlook
• 15.5 Boehringer Ingelheim GmbH
  • 15.5.1 Company Snapshot
  • 15.5.2 Company Overview
  • 15.5.3 Financial Analysis
    • 15.5.3.1 Net Revenue, 2017-2022
    • 15.5.3.2 R&D, 2017-2022
    • 15.5.3.3 Segment Market Shares, 2022
    • 15.5.3.4 Regional Market Shares, 2022
  • 15.5.4 Service Benchmarking
  • 15.5.5 Strategic Outlook
• 15.6 Catalent Inc.
  • 15.6.1 Company Snapshot
  • 15.6.2 Company Overview
  • 15.6.3 Financial Analysis
    • 15.6.3.1 Net Revenue, 2017-2022
    • 15.6.3.2 R&D, 2017-2022
    • 15.6.3.3 Segment Market Shares, 2022
    • 15.6.3.4 Regional Market Shares, 2022
  • 15.6.4 Service Benchmarking
  • 15.6.5 Strategic Outlook
• 15.7 FUJIFILM Diosynth Biotechnologies
  • 15.7.1 Company Snapshot
  • 15.7.2 Company Overview
  • 15.7.3 Financial Analysis
  • 15.7.4 Service Benchmarking
  • 15.7.5 Strategic Outlook
• 15.8 Lonza
  • 15.8.1 Company Snapshot
  • 15.8.2 Company Overview
  • 15.8.3 Financial Analysis
    • 15.8.3.1 Net Revenue, 2017-2022
    • 15.8.3.2 R&D, 2017-2022
    • 15.8.3.3 Segment Market Shares, 2022
    • 15.8.3.4 Regional Market Shares, 2022
  • 15.8.4 Service Benchmarking
  • 15.8.5 Strategic Outlook
• 15.9 Pfizer Inc.
  • 15.9.1 Company Snapshot
  • 15.9.2 Company Overview
  • 15.9.3 Financial Analysis
    • 15.9.3.1 Net Revenue, 2017-2022
    • 15.9.3.2 R&D, 2017-2022
    • 15.9.3.3 Segment Market Shares, 2022
    • 15.9.3.4 Regional Market Shares, 2022
  • 15.9.4 Service Benchmarking
  • 15.9.5 Strategic Outlook
• 15.10 Samsung Biologics
  • 15.10.1 Company Snapshot
  • 15.10.2 Company Overview
  • 15.10.3 Financial Analysis
    • 15.10.3.1 Net Revenue, 2017-2022
    • 15.10.3.2 Segment Market Shares, 2022
    • 15.10.3.3 Regional Market Shares, 2022
  • 15.10.4 Service Benchmarking
  • 15.10.5 Strategic Outlook
• 15.11 WuXi AppTec
  • 15.11.1 Company Snapshot
  • 15.11.2 Company Overview
  • 15.11.3 Financial Analysis
    • 15.11.3.1 Net Revenue, 2017-2022
    • 15.11.3.2 Segment Market Shares, 2022
  • 15.11.4 Service Benchmarking
  • 15.11.5 Strategic Outlook
• 15.12 Thermo Fisher Scientific Inc.
  • 15.12.1 Company Snapshot
  • 15.12.2 Company Overview
  • 15.12.3 Financial Analysis
    • 15.12.3.1 Net Revenue, 2017-2022
    • 15.12.3.2 R&D, 2017-2022
    • 15.12.3.3 Segment Market Shares, 2022
    • 15.12.3.4 Regional Market Shares, 2022
  • 15.12.4 Service Benchmarking
  • 15.12.5 Strategic Outlook
• 15.13 Cytiva
  • 15.13.1 Company Snapshot
  • 15.13.2 Company Overview
  • 15.13.3 Financial Analysis
    • 15.13.3.1 Net Revenue, 2017-2022
    • 15.13.3.2 R&D, 2017-2022
    • 15.13.3.3 Segment Market Shares, 2022
    • 15.13.3.4 Regional Market Shares, 2022
  • 15.13.4 Service Benchmarking
  • 15.13.5 Strategic Outlook

16 Conclusion and Recommendations

• 16.1 Concluding Remarks from
• 16.2 Recommendations for Market Players

관련자료